the bis-amidine pentamidine. We designed and synthesized a panel of novel bis-amidines and explored their anti-Toxoplasma efficacy. Methods: We designed and synthesized an array of twelve novel bisamidines. These compounds were examined for in vitro activity against T. gondii tachyzoites first using a colorimetric assay employing the β-gal producing strain RH-2F to examine the effect of the compounds over 5 days of parasite growth in human fibroblast host cells. This was followed by several immunofluorescence-based assays to determine if compounds can directly act on tachyzoites (red/green invasion assay), on an established infection of host cells (replication assay), and whether the compounds are parasiticidal, ie. can rid the host cells of tachyzoite infection after one dose (recovery assay). A rodent model of acute toxoplasmosis was established for examining in vivo efficacy of lead compounds. Results: Four of these compounds proved highly efficacious in vitro with 50% inhibitory (IC50) values ranging from 200 nM to 1.3 µM. Therapeutic indices based on the ratio between the median cell cytotoxic dose and the IC50 ranged from 4 to 84. These four compounds all inhibited tachyzoite invasion and significantly inhibited in vitro replication over a 24-hour period at nanomolar concentrations. Additionally, two of the compounds evaluated thus far appear to be parasiticidal in vitro at 1 -2 µM. Discussion: Our results suggest that bis-amidines can be designed to be effective against experimental Toxoplasma infections. The parasiticidal activity of some of the compounds make them serious candidates for further drug development. Further experiments to determine 1) in vivo efficacy in mouse models of persistent infection, and 2) synergy with antipsychotics and mood stabilizers will investigate the possibility that these compounds could be used as adjunct treatment in Toxoplasma-positive individuals suffering with schizophrenia and other psychiatric disorders. Background: People with severe mental illness (SMI) typically die 20 years earlier than the general population, largely due to smoking related diseases. Their smoking rate is alarmingly high and persistent, which contrasts sharply with the steady decline in the general population's smoking rate. Smokers with SMI are equally motivated to quit smoking, but report less encouragement to quit by health professionals and are less able to succeed. When engaged in a program, some can quit successfully, but at lower rates than for the general population. Evidence-based smoking cessation interventions, such as quitlines, are underutilised by smokers with SMI. There is an urgent need to develop highly accessible, appropriately tailored cessation services for smokers with SMI to which mental health services can routinely refer smokers, and to explore why low smoking cessation rates persist among people with SMI receiving cessation treatment. Quitlink will utilise peer workers to identify, support, and refer smokers with SMI in mental health services to Quitline, who will deliver a tailored, proactive and accessible smoking cessation intervention. Additionally, we wish to investigate participant and health worker perceptions of the support provided by Quitlink, the nature of barriers encountered and their impact on initiating and succeeding with cessation. Methods: Design: A multi-centre prospective, randomised, open, blinded endpoint (PROBE) design will be utilised to compare standard smoking
T92. QUITLINK: ACCESSIBLE SMOKING CESSATION SUPPORT FOR PEOPLE LIVING WITH SEVERE AND ENDURING MENTAL ILLNESS
Background: People with severe mental illness (SMI) typically die 20 years earlier than the general population, largely due to smoking related diseases. Their smoking rate is alarmingly high and persistent, which contrasts sharply with the steady decline in the general population's smoking rate. Smokers with SMI are equally motivated to quit smoking, but report less encouragement to quit by health professionals and are less able to succeed. When engaged in a program, some can quit successfully, but at lower rates than for the general population. Evidence-based smoking cessation interventions, such as quitlines, are underutilised by smokers with SMI. There is an urgent need to develop highly accessible, appropriately tailored cessation services for smokers with SMI to which mental health services can routinely refer smokers, and to explore why low smoking cessation rates persist among people with SMI receiving cessation treatment. Quitlink will utilise peer workers to identify, support, and refer smokers with SMI in mental health services to Quitline, who will deliver a tailored, proactive and accessible smoking cessation intervention. Additionally, we wish to investigate participant and health worker perceptions of the support provided by Quitlink, the nature of barriers encountered and their impact on initiating and succeeding with cessation. Methods: Design: A multi-centre prospective, randomised, open, blinded endpoint (PROBE) design will be utilised to compare standard smoking care alone against Quitlink. Assessments will be conducted at baseline, end of treatment, 3 months post treatment and 6 months post treatment. Setting and sample: 382 smokers will be recruited from three mental health services in Victoria: Mind Australia, Neami and Melbourne's St Vincent's hospital. Intervention: The manual guided Quitlink intervention consists of standard smoking care plus: Referral to Quitline, Quitline counselling, Quitline provision of NRT, Quitline engagement with mental health services, Quitline engagement of support network and peer worker help with participant contact. Results: As recommended by the Society for Research on Nicotine and Tobacco expert workgroup, the primary outcome measure in this study will be 6 months prolonged abstinence at the 8-month follow-up (allowing participants up to 2 months to stop). Prolonged 6-month abstinence will be defined as per the Russell Standard, i.e. self-report of abstinence for 6 months (allowing up to 5 cigarettes in total) and biochemical verification of self-reported abstinence (validated in a face-to-face visit using expired CO monitoring using a Micro+ Smokelyzer, with a reading of over 8ppm defined as a treatment failure). Discussion: Outcomes of the project will determine effectiveness and costeffectiveness of a novel and highly translatable intervention resulting from linking two existing services (Quitline and mental health peer workers). This will be the world first RCT of a Quitline intervention delivered to people with SMI that also includes a concurrent economic evaluation. As smoking is the leading cause of preventable death in people with SMI, if Quitlink is shown to be effective, it has the potential to greatly improve individuals' longevity, quality of life, mental health and reduce health care costs. This is an innovative and practical service delivery model that has the potential to ensure that smokers with SMI have access to best-practice smoking cessation treatment. Secondly, regardless of effectiveness outcomes, the project's qualitative study will provide greater insights into the barriers faced by smokers with SMI and will assist in the development of even more effective interventions.
T93. PERSONALITY TRAITS AND PSYCHOTIC SYMPTOMS IN RECENT ONSET OF PSYCHOSIS PATIENTS
Julia Sevilla-Llewellyn-Jones Background: Personality in patients with psychosis, and particularly its relation to psychotic symptoms in recent onset of psychosis (ROP) patients, is understudied. The aims of this research were, first, to study the relation between each clinically significant personality trait (CSPT) and psychotic symptoms, and second, to study the variance of each CSPT that was explained by psychotic symptoms, sex and age. Methods: Sample: Data was obtained from 94 ROP patients (78.7% males; mean age: 24.67(4.59)). Measures: The Millon Clinical Multiaxial Inventory (MCMI) and the Positive and Negative Syndrome Scale were used to assess CSPT (schizoid, avoidant, dependent, depressive, histrionic, narcissistic, antisocial, sadistic, compulsive, negativistic, masochistic, schizotypal, borderline, paranoid) and psychotic symptoms (positive, negative, disorganized, exited, and anxiety and depression). Statistical analyses: U Mann-Whitney tests and multivariate logistic regressions were carried out to test the association between clinical personality traits adjusting for symptoms, sex and age. Results: From the 94 patients, 13.9% had schizoid, 20.8% had avoidant, 7.9% had depressive, 7.9% had dependent, 5% histrionic, 15.8% narcissistic, 9.9% antisocial, 6.9 % sadistic, 14.9% compulsive, 1% negativistic, 0% masochistic,
